CTLT - Catalent, Inc.

NYSE - NYSE Delayed Price. Currency in USD
53.16
+0.46 (+0.87%)
At close: 4:02PM EDT

53.16 0.00 (0.00%)
After hours: 4:54PM EDT

Stock chart is not supported by your current browser
Previous Close52.70
Open52.92
Bid53.17 x 900
Ask53.18 x 800
Day's Range52.12 - 53.28
52 Week Range29.23 - 54.10
Volume730,865
Avg. Volume839,285
Market Cap7.746B
Beta (3Y Monthly)1.83
PE Ratio (TTM)50.82
EPS (TTM)1.05
Earnings DateAug 26, 2019 - Aug 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.40
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Catalent Announces Pricing of Private Offering of Senior Unsecured Notes Due 2027

    Catalent, Inc. (“Catalent”) (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $500.0 million in aggregate principal amount of 5.00% senior unsecured notes due 2027 (the “Notes”) at par. The Operating Subsidiary intends to use the net proceeds from the Private Offering to (i) repay in full the outstanding borrowings under its U.S. dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, (ii) pay related fees and expenses and (iii) provide cash on its balance sheet for general corporate purposes.

  • Business Wire2 days ago

    Catalent Announces Launch of Private Offering of $500 Million of Senior Unsecured Notes Due 2027

    Catalent, Inc. (“Catalent”) (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, $500 million in aggregate principal amount of senior unsecured notes due 2027 (the “Notes”) in a private offering (the “Private Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Operating Subsidiary intends to use the net proceeds from the Private Offering to (i) repay in full the outstanding borrowings under its U.S. dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, (ii) pay related fees and expenses, and (iii) provide cash on its balance sheet for general corporate purposes.

  • Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?
    Zacks7 days ago

    Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?

    Catalent (CTLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Business Wire7 days ago

    Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy

    Bristol-Myers Squibb Company (BMY) and Catalent, Inc. (CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.

  • Business Wire27 days ago

    Catalent, Inc. to Present at the Jefferies Healthcare Conference

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the Jefferies Healthcare Conference at 3:00 p.m.

  • Catalent Acquires Gene Therapy Leader Paragon Bioservices
    Zackslast month

    Catalent Acquires Gene Therapy Leader Paragon Bioservices

    Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

  • Business Wirelast month

    Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

    Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. With the addition of Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vector to deliver DNA to cells, Catalent is positioned to capitalize on strong industry tailwinds in the potentially $40 billion addressable market for gene therapies.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT

    Q3 2019 Catalent Inc Earnings Call

  • Catalent Inc (CTLT) Q3 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Catalent Inc (CTLT) Q3 2019 Earnings Call Transcript

    CTLT earnings call for the period ending March 31, 2019.

  • Catalent (CTLT) Surpasses Q3 Earnings Estimates
    Zacks2 months ago

    Catalent (CTLT) Surpasses Q3 Earnings Estimates

    Catalent (CTLT) delivered earnings and revenue surprises of 8.89% and -4.14%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire2 months ago

    Catalent, Inc. Reports Third Quarter Fiscal 2019 Results

    SOMERSET, N.J.-- -- Q3'19 revenue of $617.5 million decreased 2% as-reported, but increased 2% in constant currency, from Q3'18, while Q3'19 YTD revenue of $1,792.3 million increased 1% as-reported, or 3% in constant currency, from the prior-year period. Double-digit organic segment EBITDA growth within Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services segments; ...

  • Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks2 months ago

    Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • CNW Group2 months ago

    Global Cellulite Treatments Market Could Exceed $1.4 Billion by 2026

    PALM BEACH, Florida, April 18, 2019 /CNW/ -- The global cellulite market and its largest segment, the non-invasive treatment sector, are both expected to grow at a healthy rate. A recent industry report on the entire cellulite market (from Transparency Market Research) projected that: "The global cellulite treatment market was valued at around US$ 619.2 Million in 2017 and is anticipated to reach US$ 1,438.5 Million by 2026, expanding at a CAGR of 10.1% from 2018 to 2026. "A report on the non-invasive sector (from Future Market Insights) had an even higher projection: "The market for non-invasive treatment is expected to reach a value of over US$ 1,900 Million by the end of 2028, growing at a robust CAGR of 8.0% during the forecast period."  The Transparency report continued: "Technological advancements have and are expected to continue to increase the efficacy and ease of usage of esthetic products.

  • CNBC2 months ago

    Stocks making the biggest moves premarket: Goldman Sachs, CVS, Best Buy, Facebook & more

    Check out the companies making headlines before the bell: Goldman Sachs GS — The investment bank reported quarterly profit of $5.71 per share , beating the consensus estimate of $4.89. Revenue fell short of forecasts, however.

  • Business Wire2 months ago

    Catalent to Acquire Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

    Catalent, Inc. (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion. “Paragon’s unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth.

  • Update: Catalent (NYSE:CTLT) Stock Gained 34% In The Last Three Years
    Simply Wall St.2 months ago

    Update: Catalent (NYSE:CTLT) Stock Gained 34% In The Last Three Years

    Buying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some are likely to underperform. Unfortunately for shareholders, while the Catalent, Inc. (NYSE:CTLT) share pri...

  • Business Wire3 months ago

    Catalent, Inc. Announces Third Quarter Fiscal Year 2019 Earnings Conference Webcast

    Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the third quarter of fiscal year 2019 ended March 31, 2019, before the market open on Tuesday, May 7, 2019. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.

  • CTLT or ORINY: Which Is the Better Value Stock Right Now?
    Zacks3 months ago

    CTLT or ORINY: Which Is the Better Value Stock Right Now?

    CTLT vs. ORINY: Which Stock Is the Better Value Option?

  • CTLT or NBIX: Which Is the Better Value Stock Right Now?
    Zacks3 months ago

    CTLT or NBIX: Which Is the Better Value Stock Right Now?

    CTLT vs. NBIX: Which Stock Is the Better Value Option?

  • Is Catalent, Inc.’s (NYSE:CTLT) Balance Sheet A Threat To Its Future?
    Simply Wall St.4 months ago

    Is Catalent, Inc.’s (NYSE:CTLT) Balance Sheet A Threat To Its Future?

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Catalent, Inc. (NYSE:CTLT), with a market capitalization of US$6.2b, rarely draw their attention from the investing community.Read More...

  • Business Wire4 months ago

    Catalent, Inc. to Present at the Barclays Global Healthcare Conference

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 2:35 p.m.

  • Champions Oncology (CSBR) Q3 Earnings: What's in Store?
    Zacks4 months ago

    Champions Oncology (CSBR) Q3 Earnings: What's in Store?

    During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.

  • The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
    Zacks4 months ago

    The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris

    The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris

  • 4 Drug Stocks to Buy Despite Price Hearing Woes
    Zacks4 months ago

    4 Drug Stocks to Buy Despite Price Hearing Woes

    A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.

  • Will Catalent Continue to Surge Higher?
    Zacks4 months ago

    Will Catalent Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Catalent.